Company Overview: Isoray

Industry News

28 Nov

IsoRay to Present at the 10th Annual LD Micro Main Event

Presentation on Wednesday, December 6, 2017, at 7:30 am PST / 10:30 am EST RICHLAND, WA / ACCESSWIRE / November 28, 2017 / IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head, and...

Read more

9 Nov

IsoRay, Inc. Announces the Launch of a Phase II, Multicenter Clinical Trial with Cesium-131 Adjuvant Radiation for Retroperitoneal Sarcoma Delivery System (CARDS Trial) by University of Louisville, Division of Surgical Oncology

RICHLAND, Wash., Nov. 09, 2017 (GLOBE NEWSWIRE) — IsoRay, Inc. (ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced the launch of a Phase II, Multicenter Clinical Trial with...

Read more

8 Nov

IsoRay Announces First Quarter Fiscal 2018 Earnings Conference Call

RICHLAND, WA–(Marketwired – Nov 8, 2017) – IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will host a teleconference to...

Read more

28 Sep

IsoRay Announces Fourth Quarter Fiscal 2017 Revenue of $1.37 Million, 22% Fourth Quarter-over-Fourth Quarter Increase

Gross Margin Expands to 36% on Continued Process Improvements and Expense Reduction RICHLAND, Wash., Sept. 28, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced...

Read more

26 Sep

IsoRay Announces Study Accepted for Publication in the International Journal of Radiation Oncology, Biology, Physics entitled “Re-irradiation using Permanent Interstitial Brachytherapy (PIB): A Potentially Durable Technique for Salvaging Recurrent Pelvic Malignancies”

Study Demonstrates Ability to Control Local Disease Over Reasonably Long Period of Time, A Major Step in Preserving Quality of Life RICHLAND, Wash., Sept. 26, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain,...

Read more

25 Sep

IsoRay Announces “Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131 / Iodine-125 Permanent Prostate Brachytherapy Trial” Poster Presentation at 2017 Annual American Society for Radiation Oncology (ASTRO) Conference

9 Year Study Demonstrates Durable Positive Outcomes and Statistically Identical Results of Cesium-131 RICHLAND, Wash., Sept. 25, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today...

Read more

31 Aug

IsoRay Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017

Presenting on Monday September 11 at 12:05PM ET RICHLAND, Wash., Aug. 31, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced it will be...

Read more

6 Jul

IsoRay Receives FDA Response to 510(k) Application for GammaTile™

RICHLAND, Wash., July 6, 2017 /PRNewswire/ — IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it has received a response from the FDA regarding the Company’s...

Read more

Page 1 of 41234

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address